Perspective Therapeutics (CATX) Interest Expenses (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Interest Expenses data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 541.31% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 541.31% YoY), and the FY2025 full-year result was $3.3 billion, down 14.5% from the prior year.
• Interest Expenses climbed to $2.8 million in Q1 2026, from $1000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $41.8 million in Q4 2024 to a low of $1000.0 in Q4 2025.
• A 5-year average of $5.7 million and a median of $1.6 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 190036.36% in 2024 and sank 100.0% in 2025, its largest moves.
• Tracing CATX's Interest Expenses over 5 years: stood at $41000.0 in 2022, then slumped by 46.34% to $22000.0 in 2023, then surged by 190036.36% to $41.8 million in 2024, then slumped by 100.0% to $1000.0 in 2025, then soared by 284000.0% to $2.8 million in 2026.
• Business Quant data shows CATX's Interest Expenses at $2.8 million in Q1 2026, $1000.0 in Q4 2025, and $1.9 million in Q3 2025.